Human Oncology & Pathogenesis Program

The David Solit Lab

Research

David B. Solit, MD

Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology

Our research is based on the underlying hypothesis that the ability to inhibit an oncogenic pathway and block cancer growth will vary based on cell lineage and the complement of mutations within the tumor. To design rational therapeutic studies, we must define not only the spectrum of genetic changes within particular tumor types but also the mechanisms by which these alterations support tumor growth, survival, metastasis, and other hallmarks of cancer.

View Lab Overview

Research Projects

Featured News

Announcement

Expanding the Impact of Precision Medicine to Fuel Discoveries

Thursday, February 12, 2015

Finding Clues in Genes of ‘Exceptional Responders’

Thursday, October 9, 2014

Event

A Sneak Preview of Our Annual “Major Trends” Seminar Live Webcast

Monday, November 3, 2014

View All Featured News

Publications

Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2012 Jan 26;31(4):446-57. doi: 10.1038/onc.2011.250. Epub 2011 Jul 4.

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011 Nov 23;480(7377):387-90. doi: 10.1038/nature10662.

Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She QB, Aghajanian C, King TA, Stanchina Ed, Spriggs DR, Heguy A, Taylor BS, Sander C, Rosen N, Levine DA, Solit DB. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2012 Jan;2(1):56-67. doi: 10.1158/2159-8290.CD-11-0170.

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156.

Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Socci ND, Ostrovnaya I, Viale A, Heguy A, Peng L, Chan TA, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23.

View All Publications

People

David B. Solit, MD

Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology

Physician-scientist David Solit studies human oncology and pathogenesis, genomics, oncogenes and tumor suppressors, cancer therapeutics, and clinical trials.
MD, University of Pennsylvania

solitd@mskcc.org: Email Address
View physician profile: Physician profile

Members

Sizhi Paul Gao
Senior Research Scientist

Aphrothiti Hanrahan, PhD — Aphrothiti Hanrahan
Assistant Lab Member

Wenhuo Hu, PhD — Wenhuo Hu
Research Associate

Gopa Iyer, MD — Gopa Iyer
Assistant Attending, Genitourinary Oncology Service

Alexis M. Jones, MS — Alexis M. Jones
Research Lab Manager

Kwanghee Kim
Assistant Attending Biologist

Keshia Pierre

Program Assistant

Manisha Rao

Research Fellow

James Rodrigues

Research Technician

Naryan Rustgi

Senior Research Technician

Naresh Vasani

Research Assistant

Jessica (Ziyu) Chen

Weill Cornell Graduate Student

Arijh Elfatih Elzein

Weill Cornell Graduate School Student

Timothy Clinton

Urology Fellow

Andrew T. Lenis

Urology Fellow

Peter Reisz

Urologic Oncology Fellow

Hong Truong

Urologic Oncology Fellow

Hikmat A. Al-Ahmadie, MD — Hikmat A. Al-Ahmadie
Associate Attending Pathologist, Memorial Hospital

Abraham Ari Hakimi
Assistant Attending, Department of Surgery

Phillip Rappold

RCC Urology Fellow

Lynda Vuong

Research Fellow

Mark Donoghue, PhD — Mark Donoghue
Senior Computational Biologist

Martina Bradic

Senior Computational Biologist

Yixiao Gong
Senior Computational Biologist

Anne Marie Noronha

Bioinformatics Engineer

Vignesh Ravichandran

Senior Computational Biologist

Allison Richards, Computational Biologist II — Allison Richards
Computational Biologist

Vasilisa Rudneva
Senior Computational Biologist

Hyung Jun Woo

Senior Computational Biologist

Lab Alumni

Shweta Chavan
Senior Computational Biologist

Helen Won, MS — Helen Won
Senior Computational Biologist

Tripti Shrestha Bhattarai, PhD — Tripti Shrestha Bhattarai
Research Associate

Amber Ahmad

Research Technician

François Audenet
Urologic Oncology Fellow

David Barron, MD, PhD — David Barron
Radiation Oncology Resident

Federica Catalanotti, PhD — Federica Catalanotti
Research Fellow

Eugene K. Cha, MD — Eugene K. Cha
Assistant Attending, Urologic Oncology

Michael Cheng

Fellow

Neil Desai, MD, MHS — Neil Desai
Resident in Radiation Oncology

Noah Friedman, Computational Biologist II — Noah Friedman
Computational Biologist

Rebecca Hiner

Senior Technician

Joseph Hreiki, MD — Joseph Hreiki
Research Fellow

Manickam Janakiraman, PhD — Manickam Janakiraman
Research Associate

Philip Kim, MD — Philip Kim
Clinical Research Fellow

Byron Lee

Urology Fellow

Victor McPherson

Urology Fellow

Moriah Heller Nissan, PhD — Moriah Heller Nissan
Research Fellow

Eugene J. Pietzak
Urologic Oncology Fellow

Ricardo Ramirez
Cornell University Graduate Student

Tara Soumerai
Assistant Attending, Gynecologic Medical Oncology Service

Brooke Sylvester, PhD — Brooke Sylvester
Research Fellow

Efsevia Vakiani, MD, PhD — Efsevia Vakiani
Assistant Attending Pathologist

Hannah Wise, BS — Hannah Wise
Lead Clinical Data Analyst at Flatiron Health, New York, NY

Feng Xing, PhD — Feng Xing
Research Fellow

Kai Zhang

Graduate Research Assistant

Lab Affiliations

Achievements

Member, American Society for Clinical Investigation (2011)
Louise and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2007)
Kimmel Scholar, Sidney Kimmel Foundation for Cancer Research (2007)
Career Development Award, American Society of Clinical Oncology (2002)
Young Investigator Award, American Society of Clinical (2001)

Doris Duke Translational Award, Doris Duke Foundation (2001)
Clinical Scholars Research Fellow, National Institutes of Health (2000)

Open Positions

Career Opportunities

Apply now

Postdoc Position in Preclinical and Translational Cancer Genomics and Therapeutics

Apply now

Get in Touch

solitd@mskcc.org

Lab Head Email
646-888-2641

For non-clinical issues only
646-422-4459

For patient-related issues
646-888-2649

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David B. Solit discloses the following relationships and financial interests:

American Association for Cancer Research
Provision of Services
Eli Lilly and Company
Provision of Services
Illumina
Provision of Services
Loxo Oncology
Ownership / Equity Interests

Pfizer, Inc.
Provision of Services
Physicians' Education Resource
Provision of Services
QED Therapeutics, Inc.
Provision of Services
Vividion Therapeutics
Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

View all disclosures